Goodrx Holdings, INC 8-K filings

GoodRx Holdings, Inc. reported the final voting results from its Annual Meeting of Stockholders held on June 16, 2026, confirming the election of directors, ratification of auditors, and approval of executive compensation.

GoodRx Holdings, Inc. has promoted Thomas Chan to the role of Chief Accounting Officer, effective immediately.

GoodRx Holdings announces the resignation of Director Ian T. Clark and a subsequent board rebalancing involving CEO Wendy Barnes.

GoodRx Holdings, Inc. announced the resignation of its Chief Accounting Officer, Romin Nabiey, effective April 3, 2026, as he pursues other opportunities.

GoodRx Holdings, Inc. announced its Board of Directors approved a $72,918 discretionary cash bonus for Chief Accounting Officer Romin Nabiey for 2025 performance.

GoodRx Holdings, Inc. announced the resignation of Dipanjan Deb from its Board of Directors, effective February 26, 2026.

GoodRx Holdings, Inc. announced its fourth quarter and full year 2025 financial results, with revenue and Adjusted EBITDA in line with guidance, driven by strong Pharma Direct growth.

GoodRx Holdings, Inc. announced retention bonuses of $2 million for its CEO, Wendy Barnes, and $1 million for its CFO, Chris McGinnis, to incentivize their continued service.

GoodRx Holdings, Inc. reports mixed third-quarter 2025 results with slight revenue growth and strong pharma manufacturer solutions, but declines in net income and key consumer metrics.

GoodRx Holdings, Inc. announced that Co-Chairman Trevor Bezdek will transition from an executive officer to a non-employee director effective November 1, 2025.

GoodRx reports increased net income and Adjusted EBITDA for Q2 2025, driven by strong pharma manufacturer solutions revenue, despite declines in prescription transactions and subscription segments.

GoodRx Holdings, Inc. announced that its stockholders overwhelmingly approved all proposals at the Annual Meeting held on June 3, 2025, including the re-election of three Class II directors, the ratification of PricewaterhouseCoopers LLP as its independent auditor, and the advisory approval of executive compensation.

GoodRx's Q1 2025 revenue was in-line with expectations, while adjusted EBITDA margin exceeded previous guidance, and the company maintained its full-year revenue guidance range while raising adjusted EBITDA expectations.

GoodRx Holdings, Inc. will repurchase shares from Spectrum Equity, Francisco Partners, and Idea Men at a discounted price, utilizing its existing repurchase program.

GoodRx's Q4 and full-year 2024 results align with previous guidance, showcasing revenue growth and improved profitability.

GoodRx Holdings, Inc. has appointed Christopher A. McGinnis as its new Chief Financial Officer and Treasurer, effective February 4, 2025.

GoodRx Holdings, Inc. has appointed Scott Wagner to its Board of Directors, as Co-Chair, and Chair of the Compensation Committee, following the resignation of Simon Patterson.

GoodRx Holdings, Inc. announced the resignation of Chief Financial Officer Karsten Voermann, effective January 17, 2025, and the appointment of Romin Nabiey as Interim CFO.

GoodRx Holdings, Inc. has announced the appointment of Wendy Barnes as its new Chief Executive Officer and President, effective January 1, 2025, succeeding interim CEO Scott Wagner.

GoodRx Holdings, Inc. announced its third quarter 2024 financial results, highlighting revenue of $195.3 million and a net income of $4.0 million.

GoodRx has announced the resignation of a board member, the appointment of a new director, the transition of its Chief Mission Officer, and an amendment to the Chairman's employment agreement.

GoodRx announced its second quarter 2024 financial results, showing revenue growth but a significant decrease in net income compared to the previous year.

GoodRx has entered into a sixth amendment to its credit agreement, securing a $500 million term loan and extending its revolving credit facility.

GoodRx has appointed Ian T. Clark, former CEO of Genentech, to its Board of Directors, effective immediately, to fill a vacancy and enhance its strategic direction.

GoodRx Holdings held its annual meeting on June 6, 2024, where stockholders elected three Class I directors, ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor, and approved executive compensation on an advisory basis.

GoodRx has appointed Simon Patterson, a seasoned technology investor and executive, to its Board of Directors, filling a recent vacancy and adding significant industry experience.

GoodRx's first quarter of 2024 saw revenue growth of 8% year-over-year, but was impacted by a legal settlement and restructuring costs.

GoodRx has extended the employment agreement of its Interim CEO, Scott Wagner, and announced the resignations of two board members, Adam Karol and Stephen LeSieur.

GoodRx Holdings, Inc. has entered into a new employment agreement with Chief Financial Officer Karsten Voermann, including a special bonus and equity awards.

GoodRx has agreed to repurchase approximately $150 million of its Class A common stock from Spectrum Equity and Francisco Partners at a discount to the market price.